Out of the 701 Adverse Drug Reaction Monitoring Centers (AMCs) across the nation, 10 have been delisted by the Indian Pharmacopoeia Commission (IPC) due to poor performance in ADR reporting. The delisted hospitals include the Aundh Chest Hospital in Aundh, Maharashtra; Babu Ishwar Saran District Hospital in Gonda, Uttar Pradesh (UP); Combined District Hospital in Shrawasti, Uttar Pradesh (UP); District Hospital in Bahraich, Uttar Pradesh; District Hospital (Male), Pratapgarh, Uttar Pradesh; Glocal Group of Hospitals in Rajarhat, West Bengal; Government Medical College in Jalaun, Uttar Pradesh; Sri Krishna Medical College and Hospital.
The Pharmacovigilance Programme of India (NCC-PvPI) throughout the nation is coordinated by the IPC, which serves as its National Coordination Centre (NCC). The Ministry of Health and Family Welfare (MoHFW), Government of India (GoI), approved the PvPI in July 2010 with the main goal of developing a national system for patient safety reporting. In order to ensure patient safety, PvPI plans to incorporate pharmacovigilance (PV) as a crucial element of public health programmes (PHPs). The IPC has informed all parties involved that the AMCs named below have been removed from the PvPI due to poor performance. These delisted AMCs were enrolled during the years of 2015 and 2017, and their joining date was March 2023.
In order to specify the standards of identity, purity, and strength of the drugs imported, manufactured for sale, stocked, or displayed for sale or distribution, the Government of India (GoI) created a separate, dedicated, autonomous institution in the form of the IPC to handle matters relating to timely publication of the Indian Pharmacopoeia, which is the official book of standards for drugs included therein.
The PvPI was established with the general goal of preserving Indians’ health. ADRs are reported to NCC-PvPI from all throughout the nation, and it also collaborates with the WHO-UMC, a Swedish organisation, to add to the global ADRs database. NCC-PvPI keeps track of adverse drug reactions (ADRs) among Indians and assists India’s regulatory body (CDSCO) in making judgements regarding the safe use of medications.
